Two very different answers to knee cartilage damage

When two injection options keep appearing in a patient's research, the instinct is to ask which one is better. For ChondroFiller and Arthrosamid, that framing misses the point — they are not competing versions of the same treatment. They address different problems through fundamentally different mechanisms, and the choice between them depends on what the damaged joint actually needs, not on personal preference or a league table.

ChondroFiller is a Type I collagen scaffold that gels in situ at the site of cartilage loss. Its role is to support the body's own repair processes: the scaffold recruits the patient's progenitor cells and promotes endogenous chondrocyte differentiation — a regenerative mechanism, not a symptomatic one.

Arthrosamid is a permanent, non-biodegradable polyacrylamide hydrogel injected as a single 6 mL dose. It integrates into the synovial membrane over weeks, forming a cushioning sub-synovial layer that reduces mechanical load on the joint surface. It does not repair cartilage and is not designed to fill structural defects.

The practical implication is that this is a pathology match, not a ranking: identifiable cartilage loss with some residual regenerative capacity points toward ChondroFiller; established OA-pattern disease where durable pain cushioning is the primary need points toward Arthrosamid. Neither product has been tested against the other in a controlled trial, and individual assessment is needed before either is appropriate.

How ChondroFiller works as an injectable scaffold

Placed under ultrasound guidance in an outpatient clinic appointment — no theatre admission, no incisions — ChondroFiller is delivered as a liquid collagen solution that sets in position at body temperature once it reaches the cartilage surface, forming a three-dimensional matrix at the site of damage.

The technical term for what follows is acellular matrix-induced chondrogenesis. The scaffold itself contains no cells; its structure instead acts as a chemotactic signal, drawing the patient's own progenitor cells — from the surrounding synovium and the subchondral bone beneath the lesion — into the gel. Once recruited, those cells begin differentiating toward a chondrocyte-like phenotype and laying down repair tissue from within. A 2025 ex vivo explant study measured this recruitment directly: compared with untreated defects, ChondroFiller-treated sites showed a 2.4-fold increase in DNA content by day 14, confirming that active cellular migration into the scaffold was well under way within the first two weeks.

Because the collagen matrix is biodegradable, it functions as a temporary framework rather than a permanent addition to the joint. As repair tissue matures, the scaffold is gradually resorbed — the aim being that endogenous tissue replaces it over time.

One practical expectation worth carrying into this process: a protected weight-bearing period forms part of the post-injection protocol. A biomechanical in-vitro study found that in the acute phase, before the gel has fully stabilised, it does not yet provide complete load protection. Activity restriction during this window is a clinical recommendation, not an optional precaution.

What Arthrosamid does — and where it stops

Arthrosamid's mechanism begins in the synovial membrane, not at the cartilage surface. The product — 2.5% cross-linked polyacrylamide in 97.5% water — is administered as a single 6 mL intra-articular injection. Over the following 30 to 90 days it integrates into the synovial lining via a low-level macrophage-mediated foreign body response, producing a stable sub-synovial cushioning layer that reduces mechanical load transmitted across the joint. In animal models this integrated structure persisted for up to two years.

That mechanism is symptomatic by design. Arthrosamid does not fill focal cartilage defects, recruit repair cells, or stimulate endogenous tissue production. Where ChondroFiller functions as a temporary scaffold intended to be progressively replaced by repair tissue, Arthrosamid remains permanently in the joint — a distinction that carries a documented safety question.

Residual acrylamide monomer — a known neurotoxin and suspected carcinogen — may leach slowly from the permanent polyacrylamide matrix over time. Internal analysis of the product frames this as a borderline regulatory issue: whether Arthrosamid should be classified as a medical device or a medicinal product depends in part on whether that monomer release is considered pharmacological in nature. This has not been established as a proven clinical harm, but it is a material contrast with biodegradable scaffolds such as ChondroFiller's collagen matrix.

The indicated patient group follows from all of this: OA-pattern knee disease where the primary unmet need is durable pain cushioning, typically after hyaluronic acid or corticosteroid has not provided lasting relief. Discrete focal chondral lesions, where structural repair capacity may still be present, fall outside Arthrosamid's clinical model.

What the clinical evidence shows for each

Across knee studies, ChondroFiller consistently produces IKDC score improvements of approximately 30 points at 12 months, with a reported complication rate near zero and a reoperation rate of 3–8% — a meaningful contrast with microfracture, where reoperation rates in the same literature reach up to 41%. A 2016 multicentre RCT reinforced this picture: the ChondroFiller group (n=13) showed statistically significant IKDC gains at 3, 6, and 12 months, with MRI confirming good defect filling from early in the follow-up period. The comparison with microfracture remained partial, however — six of ten control-arm patients declined surgery, preventing formal statistical analysis between groups.

For Arthrosamid, a 2022 PRISMA systematic review covering 463 patients found statistically significant pain and function improvements at 52 weeks and sustained to two years; an included RCT showed numerically superior outcomes versus hyaluronic acid. A 2025 retrospective cohort (n=150, Kellgren–Lawrence grade II–IV) qualified that picture: iPAAG outperformed corticosteroid at six months (p<0.001), but at twelve months showed no statistically significant advantage over hyaluronic acid (p=0.128). Both HA and corticosteroid returned to baseline by that point, while iPAAG showed only marginal persistence — tempering claims of long-term superiority over standard viscosupplementation.

Neither product has been tested against the other in a head-to-head trial. Direct comparison is further complicated by the studies recruiting fundamentally different patient populations — focal cartilage defects in the ChondroFiller literature, diffuse OA-pattern disease in the Arthrosamid data — which makes indirect inference unreliable.

Which patients are candidates for which treatment

MRI-confirmed focal or diffuse cartilage loss with some remaining repair capacity is the core signal for ChondroFiller. Grade III and IV defects — whether discrete and contained or spread more diffusely across the load-bearing surface — sit within its indicated range, and there is no upper age limit for the injectable scaffold pathway. What does narrow candidacy is the extent of background joint disease. Hip arthroscopy data (n=26, follow-up 12–60 months) showed that patients with Tönnis Grade 2–3 pre-existing osteoarthritis had uniformly poor outcomes from the collagen scaffold, whilst those without advanced degenerative change fared well in 17 of 21 cases. The same principle carries across to the knee: where cartilage loss has progressed to near bone-on-bone change, the regenerative substrate the scaffold depends on is substantially depleted, and outcomes are likely to reflect that.

When structural repair capacity is not present, the clinical question shifts toward symptom management. Arthrosamid's cushioning mechanism is appropriate for confirmed OA-pattern knee disease — diffuse, symptomatic, and inadequately controlled by hyaluronic acid or corticosteroid — rather than for discrete focal defects where the tissue environment may still support repair.

One practical factor specific to ChondroFiller is the post-injection weight-bearing phase. The collagen gel requires a period of stabilisation before full load is applied, and patients who cannot temporarily modify their activity should raise this at the assessment appointment. It is not a deterrent for most, but it is a relevant variable for some working patterns or home circumstances.

Neither treatment decision can be made reliably on symptoms alone. MRI-guided assessment is the gating step — the scan confirms cartilage status, defect morphology, and OA grade, and that information determines whether regenerative capacity is present and which pathway is appropriate.

Getting the right assessment in London

The decision between ChondroFiller and Arthrosamid — or whether either is appropriate at all — ultimately turns on a single question: is there viable cartilage tissue remaining that a regenerative scaffold can work with, or has the joint reached a stage where durable cushioning is the more realistic clinical aim? That question cannot be answered by comparing the two treatments in the abstract; it is answered by imaging and clinical assessment of the individual joint.

London Cartilage Clinic, based on Harley Street, provides specialist cartilage and joint-preservation assessments and delivers ChondroFiller as an ultrasound-guided outpatient injection for suitable candidates. To arrange an assessment, visit londoncartilage.com.

1. [1] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. (2022). https://doi.org/10.18103/mra.v10i8.2950 https://doi.org/10.18103/mra.v10i8.2950
5. [5] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
6. [6] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655
7. [7] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12–60 month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002